- Open Access
The SARS Coronavirus S Glycoprotein Receptor Binding Domain: Fine Mapping and Functional Characterization
© Chakraborti et al; licensee BioMed Central Ltd. 2005
Received: 18 July 2005
Accepted: 25 August 2005
Published: 25 August 2005
The entry of the SARS coronavirus (SCV) into cells is initiated by binding of its spike envelope glycoprotein (S) to a receptor, ACE2. We and others identified the receptor-binding domain (RBD) by using S fragments of various lengths but all including the amino acid residue 318 and two other potential glycosylation sites. To further characterize the role of glycosylation and identify residues important for its function as an interacting partner of ACE2, we have cloned, expressed and characterized various soluble fragments of S containing RBD, and mutated all potential glycosylation sites and 32 other residues. The shortest of these fragments still able to bind the receptor ACE2 did not include residue 318 (which is a potential glycosylation site), but started at residue 319, and has only two potential glycosylation sites (residues 330 and 357). Mutation of each of these sites to either alanine or glutamine, as well as mutation of residue 318 to alanine in longer fragments resulted in the same decrease of molecular weight (by approximately 3 kDa) suggesting that all glycosylation sites are functional. Simultaneous mutation of all glycosylation sites resulted in lack of expression suggesting that at least one glycosylation site (any of the three) is required for expression. Glycosylation did not affect binding to ACE2. Alanine scanning mutagenesis of the fragment S319–518 resulted in the identification of ten residues (K390, R426, D429, T431, I455, N473, F483, Q492, Y494, R495) that significantly reduced binding to ACE2, and one residue (D393) that appears to increase binding. Mutation of residue T431 reduced binding by about 2-fold, and mutation of the other eight residues – by more than 10-fold. Analysis of these data and the mapping of these mutations on the recently determined crystal structure of a fragment containing the RBD complexed to ACE2 (Li, F, Li, W, Farzan, M, and Harrison, S. C., submitted) suggested the existence of two hot spots on the S RBD surface, R426 and N473, which are likely to contribute significant portion of the binding energy. The finding that most of the mutations (23 out of 34 including glycosylation sites) do not affect the RBD binding function indicates possible mechanisms for evasion of immune responses.
Viral envelope glycoproteins initiate entry of viruses into cells by binding to cell surface receptors followed by conformational changes leading to membrane fusion and delivery of the genome to the cytoplasm . The spike (S) glycoproteins of coronaviruses are no exception and mediate binding to host cells followed by membrane fusion; they are major targets for neutralizing antibodies and form the characteristic corona of large, distinctive spikes in the viral envelopes [2, 3]. Such 20 nm complex surface projections also surround the periphery of the SCV particles . The level of overall sequence similarity between the predicted amino acid sequence of the SCV S glycoprotein and the S glycoproteins of other coronaviruses is low (20–27% pairwise amino acid identity) except for some conserved sequences in the S2 subunit . The low level of sequence similarity precludes definite conclusions about functional and structural similarity.
The full-length SCV S glycoprotein and various soluble fragments have been recently cloned, expressed and characterized [6–11]. The S glycoprotein runs at about 170–200 kDa in SDS gels suggesting posttranslational modifications as predicted by previous computer analysis and observed for other coronaviruses [6, 11]. S and its soluble ectodomain, Se, were not cleaved to any significant degree . Because the S protein of coronaviruses is a class I fusion protein , this observation classifies the SCV S protein as an exception to the rule that class I fusion proteins are cleaved exposing an N-terminal fusogenic sequence (fusion peptide) although cleavage of S could enhance fusion .
Because S is not cleaved, it is difficult to define the exact location of the boundary between S1 and S2; presumably it is somewhere between residues around 672 and 758 [6, 7]. Fragments containing the N-terminal amino acid residues 17 to 537 and 272 to 537 but not 17 to 276 bound specifically to Vero E6 cells and purified soluble receptor (ACE2) molecules . Together with data for inhibition of binding by antibodies, developed against peptides from S, these findings suggested that the receptor-binding domain (RBD) is located between amino acid residues 303 and 537 . Two other groups obtained similar results and found that independently folded fragments containing residues 318 to 510  and 270 to 510  can bind receptor molecules. Currently, these fragments are being further characterized to better understand the interactions of the virus with its receptor as well as their potential as inhibitors of the virus entry by blocking these interactions. Here, we present evidence that glycosylation of these and other fragments containing the S RBD does not affect to any measurable degree their binding to the receptor (ACE2), and analyze the S RBD-ACE2 interaction.
A short RBD fragment containing only two potential glycosylation sites folds independently and binds ACE2
S RBD mutants, expression levels and binding to ACE2.
The potential glycosylation sites in RBD fragments are functional and glycosylation does not affect binding to ACE2
Only one glycosylation site is required for secretion of functional RBD fragments
Identification of 11 RBD amino acid residue mutations that affect its binding to ACE2, and 20 – that do not
To identify RBD amino acid residues that might affect binding to ACE2, we converted 32 residues in S319–518 to alanine, expressed the mutants and tested their binding to ACE2. Eleven mutants, K390, R426, D429, T431, D454, I455, N473, F483, Q492, Y494, and R495 exhibited decreased binding to ACE2 at comparable levels of expression (Table 1). Note that RBD fragment mutated at D454 or Y494 was expressed at somewhat lower levels but binding was much more significantly reduced. In addition, one of these mutations, D454, was previously shown to affect the RBD-ACE2 interaction . The T431 mutation reduced binding but to lesser extent than the other mutations that decreased very significantly (more than 10-fold) the RBD-ACE2 interaction. The protein mutated at R441 expressed poorly and we were not able to assess its role in the RBD binding, although because of the similar levels of decrease in binding and expression, it is likely that this mutation does not affect binding. Interestingly, it appears that the D393 mutation enhanced binding – the mutated fragment expressed at low concentration but its binding equaled the binding of the non-mutated protein. The mutated residues that affect RBD binding include positively and negatively charged, polar and hydrophobic residues, indicating a role of electrostatic and hydrophobic interactions in the RBD-ACE2 interactions. These results also demonstrate that the mutations for the selected panel of residues that do affect binding are significantly (about 2-fold) more than those that do not, suggesting possible mechanisms of immune evasion.
Analysis of the S RBD sequence and the role of critical residues in S RBD
In the structure of the S RBD-ACE2 complex two of the mutants with very significantly reduced binding to ACE2, R426A and N473A, make contacts with ACE2 residues and are completely exposed (Table 1). They are separated by residues whose mutations do not affect the S RBD binding to ACE2. Interestingly, six of the mutations we identified to reduce binding are buried but at close proximity to R426 as shown by the translucent surface highlighting in Fig. 6B indicating sensitivity of this area to mutations and likely involvement of other residues. Residues D454 and I455, whose mutation reduced binding to ACE2, do not make contacts with ACE2 and are located on the side opposing the side facing the receptor (right panel of Fig. 6); it is likely that the mutations decrease binding by inducing conformational changes. Other mutations including mutations of the two glycosylations sites on that side do not affect binding to ACE2 (right panels of Fig. 6). These results suggest the existence of two hot spots on the S RBD surface, R426 and N473, which are likely to contribute significant portion of the binding energy.
The major results of this work are the demonstration of the functionality of the potential glycosylation sites of the S RBD and the requirement of at least one of them for its proper expression as well as the identification of two hot spots on the S RBD surface, R426 and N473, which are likely to contribute significant portion of the binding energy to ACE2. ACE2 was previously identified as a receptor for the SCV  and this finding was confirmed [6, 13]. ACE2 binds with high (nM) affinity to S and is expected to induce conformational changes required for membrane fusion [6–8, 14]. Its crystal structure was recently reported  and is in general agreement with two homology models previously developed [16, 17]. It was proposed that the S binding domain on ACE2 involves residues on the ridges surrounding the enzymatic site . Recently, several ACE2 regions and amino acid residues were identified as important for its binding to the S RBD .
Currently, the three-dimensional (3D) structure of the S RBD in free unbound form is unknown. We performed sequence analysis and developed a 3D model of a fragment containing the S RBD (the model will be described elsewhere). According to this model the S RBD like RBDs from other viruses contains predominantly β-sheets. Most of the residues affecting the ACE2 interactions are exposed on the surface of the beta sheets and inter-connecting loops. These predicted observations are consistent with the recently solved crystal structure of S RBD complexed with ACE2 (Li, F, Li, W, Farzan, M, and Harrison, S. C., submitted). The nature of the residues, which include charged, hydrophobic and polar residues indicated that all these types of interactions could be involved either directly or indirectly in the S RBD binding to ACE2. Notable are the complementarities in the charges of several residues in S, e.g. R426 and N473 with those of ACE2, e.g. E329 and Q24, respectively. One can reason that these residues might contribute significantly for the on rate constant and proper orientation of the two molecules in the complex, as well as to the low dissociation rate constant. We identified two hot spots, residues R426 and N473, which are likely to contribute to the bulk of the free energy of interaction. Further studies are required for the elucidation of the energy profile of the S RBD-ACE2 interaction.
We found that not only glycosylation of the three sites in the previously described RBD-containing fragments is dispensable for expression (except one that can be any) but it also does not affect binding to ACE2. Indeed all glycosylation sites are localized at the N-terminal portion of the RBD and are relatively close to each other not only in the sequence (residues 318, 330 and 357) but also in the 3D space (Fig. 6). We constructed a fragment (319–518), which contains only two glycosylation sites and still binds with an affinity undistinguishable from the fragments containing three glycosylation sites. Further mutations of all combinations of these sites revealed that only one of them is required for expression but none of them for binding. Therefore the S RBD contacts ACE2 by an area lacking carbohydrates, which is in agreement with the recently solved crystal structure of the S RBD (Li, F, Li, W, Farzan, M, and Harrison, S. C., submitted).
The entry of the SCV into cells can be inhibited by antibodies that bind the S glycoprotein and prevent its binding to ACE2. Such a monoclonal antibody that potently inhibits membrane fusion at nM concentrations was recently identified by screening phage display libraries . This antibody competed with ACE2 for binding to the S glycoprotein suggesting that its mechanism of neutralization involves inhibition of the virus-receptor interaction. We have also identified several antibodies specific for the S RBD ( and Zhu and Dimitrov, in preparation). The mutants developed in this study could be useful for mapping the epitopes of the antibodies against the S RBD, most of which are likely to neutralize the virus by preventing binding to the receptor ACE2.
Most of the mutations (20) described in this study did not affect binding of the S RBD to ACE2. This finding suggests that the virus could easily mutate and escape antibodies that do not exhibit the same energy profile of binding to S as ACE2. However, further studies are required in the context of the whole oligomeric S protein to make more definite conclusions about possible mechanisms of immune evasion.
The results reported in this study could have implications for understanding the mechanisms of SCV entry, and for development of entry inhibitors, vaccine immunogens, and research tools. Future studies particularly the solution of the crystal structure of the S protein in free unbound form, and in complex with ACE2, as well as measurements of the energy profiles of binding to ACE2 and antibodies, could elucidate detailed mechanisms of the S RBD function that may help in the further development of clinically useful inhibitors and vaccines.
Plasmids and antibodies
Plasmid encoding the soluble form of ACE2, pCDNA3-ACE2-ecto, was kindly provided by M. Farzan from Harvard Medical School, Boston, Massachusetts. VTF7.3 is a kind gift from C. Broder, USUHS, Bethesda, MD. Expression vectors pSecTag2 series were purchased from Invitrogen (Carlsbad, California). The monoclonal anti-c-Myc epitope antibodies (unconjugated and conjugated to HRP) were obtained from Invitrogen (Carlsbad, CA).
Cloning of S fragments
Using the previously described S756  plasmid as template, fragments S364–537 (5'-GATCGGATCCTCAACCTTT AAGTGC-3' and 5'-GATCGAATTCC AGTAC CAGTGAG-3'), S317–518 (5'-GATCGGATCCCCTAATATTACAAAC-3' and 5'-G ATCGAATTCGGTCAGTGG-3'), S317–471 (5'-GATCGGATCC CCTAATATTAC AAAC-3' and 5'-GATCGAATTCGAGCAGGTGGG-3'), S329–518 (5'-GATCGGA TCCTTCCC TTCTGTC-3' and 5'-GATCGAATTCG GTCAGTGG-3'), S329–458 (5'-GATC GGATCCTTCCCTTCTGTC-3' and 5'-GATCGAATTCGCACATTAGA TATGTC-3'), S319–518 (5'-GATCGGATCCA TTACAAACTTGTGTCC-3' and 5'-GATCGAATTCG GTCAGTGG-3'), S399–518 (5'-GATCGGATCCCCAGG ACAA ACTGG-3' and 5'-GA TCGAAT TCGGTCAGTGG-3'), and S317–493 (5'-GATCG GATCCCCTAATATTACA AAC-3' and 5'-GATCGAATTCAAGG TTGGTAGCC-3') were PCR amplified using the primers mentioned within the parentheses. The PCR amplified fragments were then directionally cloned into expression vector pSecTag 2B using the restriction enzymes Bam HI and Eco RI. The various mutations on S317–518 and S319–518 were generated using the QuickChange® XL Site Directed Mutagenesis kit (Stratagene, La Jolla, CA) following the manufacturer's protocol.
Various plasmids were transfected into 293 cells using the Polyfect transfection kit from Qiagen (Valencia, CA) following the manufacturer's protocol. Four hours after transfection, cells were infected with VTF7.3 recombinant vaccinia virus encoding the gene for the T7 polymerase. The soluble S fragments were obtained from the cell culture medium.
Loading buffer and DTT (final concentration 50 mM) were added to either S proteins concentrated from the culture supernatant using Ni-NTA agarose beads or directly to the supernatant, boiled and run on an SDS-PAGE. The monoclonal anti-c-Myc epitope antibody (Invitrogen, Carlsbad, CA) was diluted in TBST buffer and incubated with the membrane for 2 hours, washed and then incubated with the secondary antibody conjugated with HRP for 1 hour, washed four times, each time for 15 min, and then developed using the ECL reagent (Pierce, Rockford, IL).
Cell binding assay
Medium containing soluble S fragments was collected and cleared by centrifugation. Vero E6 cells (5 × 106) were incubated with 0.5 ml of cleared medium containing soluble S fragments and 2 μg of anti-c-Myc epitope antibody conjugated with HRP at 4°C for two hours. Cells were then washed three times with ice cold PBS and collected by centrifugation. The cell pellets were incubated with ABTS substrate from Roche (Indianapolis, IN) at RT for 10 min., the substrate was cleared by centrifugation, and OD405 was measured.
For the detection of the S protein fragments, a sandwich ELISA was used in which the plate was coated with anti-His tag antibody. The S protein containing culture supernatants were added and detected with an anti-c-Myc epitope antibody. In the second ELISA, the S protein was bound to the C9-tagged ecto-domain of receptor ACE 2 that was captured on a plate coated with anti-C9 antibody (ID4). As in the previous ELISA, the S protein was detected with anti-c-myc epitope antibody. The second ELISA was used to score the binding of the various S protein fragments to the receptor ACE 2. In all experiments, the incubations with the c-myc epitope antibody were for 2 h at RT.
Sequence analysis of S RBD
Sequence similarity searches were performed using NCBI BLAST program  by selecting, separately, all non-redundant sequences (nr) and sequences derived from the 3-dimensional structure records from the Protein Data Bank (PDB). The BLAST analysis against nr database showed 19 SARS CoV-related sequences from different clones with identities of 97–99% from the top of the list as well as 7 different coronaviruses from other organisms which share only 20–35% sequence identities at the bottom. These sequences were collected and aligned with the sequence of SARS RBD fragment using ClustalW program  with default parameters. The multiple alignment sequence table was prepared by choosing the aligned sequences with optimal gaps and then a phylogram tree was constructed based on that alignment scores for the 7 different coronaviruses along with S RBD. Further, the BLAST against PDB database retrieved 5 hits and 4 of them have longer stretch of amino acids (PDB codes: 1KS5, 1K0H, 1NKG and 1QR0), which have detectable sequence similarities with different regions of SARS RBD.
We thank M. Farzan for reagents, Stephen Harrison for supplying the co-ordinates of S RBD before publication and Advanced Biomedical Computing Center (ABCC), NCI-Frederick for the computing facilities.
- Dimitrov DS: Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2004, 2: 109-122. 10.1038/nrmicro817View ArticlePubMedGoogle Scholar
- Holmes KV: SARS-associated coronavirus. N Engl J Med 2003, 348: 1948-1951. 10.1056/NEJMp030078View ArticlePubMedGoogle Scholar
- Lai MM, Cavanagh D: The molecular biology of coronaviruses. Adv Virus Res 1997, 48: 1-100. 10.1016/S0168-1702(96)01421-9View ArticlePubMedGoogle Scholar
- Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al.: A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003, 348: 1953-1966. 10.1056/NEJMoa030781View ArticlePubMedGoogle Scholar
- Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, et al.: Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300: 1394-1399. 10.1126/science.1085952View ArticlePubMedGoogle Scholar
- Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, Dimitrov DS: The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 2003, 312: 1159-1164. 10.1016/j.bbrc.2003.11.054View ArticlePubMedGoogle Scholar
- Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al.: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426: 450-454. 10.1038/nature02145View ArticlePubMedGoogle Scholar
- Wong SK, Li W, Moore MJ, Choe H, Farzan M: A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 2004, 279: 3197-3201. 10.1074/jbc.C300520200View ArticlePubMedGoogle Scholar
- Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P: Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A 2004, 101: 4240-4245. 10.1073/pnas.0306446101PubMed CentralView ArticlePubMedGoogle Scholar
- Babcock GJ, Esshaki DJ, Thomas WD Jr, Ambrosino DM: Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 2004, 78: 4552-4560. 10.1128/JVI.78.9.4552-4560.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, et al.: Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 2004, 101: 6641-6646. 10.1073/pnas.0401939101PubMed CentralView ArticlePubMedGoogle Scholar
- Bosch BJ, van der ZR, de Haan CA, Rottier PJ: The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 2003, 77: 8801-8811. 10.1128/JVI.77.16.8801-8811.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Wang P, Chen J, Zheng A, Nie Y, Shi X, Wang W, et al.: Expression cloning of functional receptor used by SARS coronavirus. Biochem Biophys Res Commun 2004, 315: 439-444. 10.1016/j.bbrc.2004.01.076View ArticlePubMedGoogle Scholar
- Dimitrov DS: The secret life of ACE2 as a receptor for the SARS virus. Cell 2003, 115: 652-653. 10.1016/S0092-8674(03)00976-0View ArticlePubMedGoogle Scholar
- Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, et al.: ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem 2004, 279: 17996-18007. 10.1074/jbc.M311191200View ArticlePubMedGoogle Scholar
- Guy JL, Jackson RM, Acharya KR, Sturrock ED, Hooper NM, Turner AJ: Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry 2003, 42: 13185-13192. 10.1021/bi035268sView ArticlePubMedGoogle Scholar
- Prabakaran P, Xiao X, Dimitrov DS: A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem Biophys Res Commun 2004, 314: 235-241. 10.1016/j.bbrc.2003.12.081View ArticlePubMedGoogle Scholar
- Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, et al.: Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005, 24: 1634-1643. 10.1038/sj.emboj.7600640PubMed CentralView ArticlePubMedGoogle Scholar
- Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, et al.: Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 2004, 101: 2536-2541. 10.1073/pnas.0307140101PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang MY, Choudhry V, Xiao X, Dimitrov DS: Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. Curr Opin Mol Ther 2005, 7: 151-156.PubMedGoogle Scholar
- McGinnis S, Madden TL: BLAST: at the core of a powerful and diverse set of sequence analysis tools. Nucleic Acids Res 2004, 32: W20-W25. 10.1093/nar/gnh003PubMed CentralView ArticlePubMedGoogle Scholar
- Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, et al.: Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003, 31: 3497-3500. 10.1093/nar/gkg500PubMed CentralView ArticlePubMedGoogle Scholar
- Lee B, Richards FM: The interpretation of protein structures: estimation of static accessibility. J Mol Biol 1971, 55: 379-400. 10.1016/0022-2836(71)90324-XView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.